Korro Bio, Inc. (KRRO) Surges 29.7%: Is This an Indication of Further Gains?

Zacks
Ouvrir sur Zacks
Korro Bio, Inc. (KRRO) Surges 29.7%: Is This an Indication of Further Gains?

Korro Bio, Inc. (KRRO) shares ended the last trading session 29.7% higher at $12.05. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 5.5% loss over the past four weeks.

Korro Bio’s share price gained after the company announced encouraging preclinical results for KRRO-111, an investigational RNA-editing therapy for alpha-1 antitrypsin deficiency (AATD). In animal studies, the candidate helped restore functional M-AAT protein while reducing harmful Z-AAT protein in the liver, potentially addressing both lung and liver damage caused by the disease. The therapy also showed strong and sustained activity with subcutaneous dosing. Korro plans to submit a regulatory filing in the first half of 2027, ahead of advancing KRRO-111 into clinical trials.

This company is expected to post quarterly loss of $1.14 per share in its upcoming report, which represents a year-over-year change of +40.6%. Revenues are expected to be $1.5 million, up 37.6% from the year-ago quarter.

While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For Korro Bio, Inc., the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on KRRO going forward to see if this recent jump can turn into more strength down the road.

 

The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Korro Bio, Inc. belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, Journey Medical Corporation (DERM), closed the last trading session 6% higher at $5.09. Over the past month, DERM has returned -26.2%.

For Journey Medical, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.02. This represents a change of +122.2% from what the company reported a year ago. Journey Medical currently has a Zacks Rank of #3 (Hold).

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Korro Bio, Inc. (KRRO): Free Stock Analysis Report
 
Journey Medical Corporation (DERM): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research